Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 337

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 337
---
 defined in Rule
200 of Regulation SHO of the Exchange Act) of our Depositary Shares or any hedging transaction, which establishes a net short position
with respect to our Depositary Shares. The Selling Shareholder has agreed that during the term of the Purchase Agreement, neither the
Selling Shareholder, nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the
foregoing transactions.

We have advised the Selling
Shareholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Shareholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.

This offering will terminate
on the date that all of our Depositary Shares offered by this prospectus have been sold by the Selling Shareholder.

Our Depositary Shares are
currently listed on The NASDAQ Capital Market under the symbol “BDRX.”

| 169 |

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets
forth the expenses payable by us in connection with the sale and distribution of the securities being registered hereby. All amounts shown,
other than the SEC registration fee, are estimates:

| SEC registration fee         | $ | 23,304 |
| Depositary fees and expenses |   |      * |
| Printing and engraving       |   |      * |
| Accounting services          |   |      * |
| Legal fees and expenses      |   |      * |
| Miscellaneous                |   |      * |
| Total                        | $ |      * |

_______________

*These fees are calculated based on the securities offered and number
of issuances and accordingly cannot be defined at this time.

<div align='center'>LEGAL MATTERS</div>

Certain legal matters in connection
with the validity of the securities offered hereby will passed upon for us by Brown Rudnick LLP, London, United Kingdom. Certain other matters of U.S. federal law will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky